(Q42280643)

19 October 2017

Respiratory syncytial virus immunization program for the United States: impact of performance determinants of a theoretical vaccine (English)

1 reference

19 October 2017

United States of America

0 references

immunization

0 references

author name string

Stephane A Régnier

series ordinal

1

1 reference

PubMed ID

23896421

19 October 2017

language of work or name

English

0 references

publication date

27 July 2013

1 reference

19 October 2017

1 reference

19 October 2017

31

1 reference

19 October 2017

40

1 reference

19 October 2017

4347-4354

1 reference

Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV) infection

19 October 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.024

Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.024

Recurrent wheezing in the third year of life among children born at 32 weeks' gestation or later: relationship to laboratory-confirmed, medically attended infection with respiratory syncytial virus during the first year of life

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.024

The role of immunoprophylaxis in the reduction of disease attributable to respiratory syncytial virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.024

Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.024

Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.024

From the American Academy of Pediatrics: Policy statements--Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.024

Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.024

Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.024

Passive protection against respiratory syncytial virus disease in infants: the role of maternal antibody.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.024

The use of health economics to guide drug development decisions: Determining optimal values for an RSV-vaccine in a model-based scenario-analytic approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.024

The cost-effectiveness of a hypothetical respiratory syncytial virus vaccine in the elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.024

Cost-effectiveness of potential infant vaccination against respiratory syncytial virus infection in The Netherlands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.024

Mathematical modelling of respiratory syncytial virus (RSV): vaccination strategies and budget applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.024

Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: A randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.024

Booster vaccination of pre-school children with reduced-antigen-content diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine co-administered with measles-mumps-rubella-varicella vaccine: a randomized, controlled trial in children pr

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.024

The burden of respiratory syncytial virus infection in young children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.024

Mortality associated with influenza and respiratory syncytial virus in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.024

Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.024

Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.024

Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.024

Respiratory morbidity 20 years after RSV infection in infancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.024

Variations in population health status: results from a United Kingdom national questionnaire survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.024

Assessing the health of the nation. The predictive validity of a preference-based measure and self-rated health

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.024

Health-state valuations for pertussis: methods for valuing short-term health states

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.024

Incremental direct expenditure of treating asthma in the United States.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.024

Time and out-of-pocket costs associated with respiratory syncytial virus hospitalization of infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.024

Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.024

Cost-effectiveness and potential impact of rotavirus vaccination in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.024

Vaccination coverage among U.S. children aged 19-35 months entitled by the Vaccines for Children program, 2009.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.024

The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32–35 weeks: a Canadian-based analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.024

Use of palivizumab in primary practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.024

Cost utility of palivizumab prophylaxis among pre-term infants in the United States: a national policy perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.024

Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.024

Productivity costs in economic evaluations: past, present, future.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.024

The level and duration of RSV-specific maternal IgG in infants in Kilifi Kenya

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.024

Immunoglobulin profile of the preterm baby

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.024

Respiratory syncytial virus specific serum antibodies in infants under six months of age: limited serological response upon infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.024

Evidence for a causal relationship between respiratory syncytial virus infection and asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.024

Impact of transmission dynamics on the cost-effectiveness of rotavirus vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.024

Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.024

Distinct patterns of evolution between respiratory syncytial virus subgroups A and B from New Zealand isolates collected over thirty-seven years.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.024

Genetic variability in envelope-associated protein genes of closely related group A strains of respiratory syncytial virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.024

10.1016/J.VACCINE.2013.07.024

7 January 2021

Identifiers

DOI

1 reference

19 October 2017

1 reference

PubMed ID

23896421